Drug discovery

Showing 9 of 0 results

• SITC Symposium: A New Era of Precision Immuno-Oncology Research Fueled by Omics-Based Technology, Testing, and Linked RWD
  • Real-world evidence
  • Drug discovery
• How advances in molecular profiling and linked real-world clinico-omics data are launching a new era of precision oncology
  • Real-world evidence
  • Precision medicine
  • Article
  • Drug discovery
• ASCO 2024 reflections and highlights
  • Real-world evidence
  • Clinical research
  • Event recap
  • Drug discovery
  • Prospective study
  • Breast cancer
  • Trial design
  • Artificial intelligence
• Effectiveness of PARP inhibitor maintenance therapy in advanced ovarian cancer by BRCA1/2 and HRD signature in real-world practice

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Comparative effectiveness
  • Drug discovery
  • Ovarian cancer
• Tumor mutational burden measurement from an FDA-approved assay and real-world overall survival on single-agent immune checkpoint inhibitors in over 8,000 patients across 24 cancer types

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Drug discovery
  • Tumor agnostic
• Metastatic patterns and outcomes by HER2 and hormone receptor status in patients with metastatic breast cancer

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Machine learning
  • Drug discovery
  • Metastatic breast cancer
  • Breast cancer
• Practice- and provider-level inequities in next-generation sequencing testing by race/ethnicity for patients with advanced non-small cell lung cancer treated in the community setting

  ASCO Annual Meeting

  • Publication summary
  • Publications
  • Health equity
  • Drug discovery
  • Non-small cell lung cancer
• Association between post-treatment alpha-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma

  Cancer

  • Publication summary
  • Publications
  • Drug discovery
  • Hepatocellular carcinoma
• Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

  Blood Cancer

  • Real-world evidence
  • Publication summary
  • Publications
  • Drug discovery
  • Multiple myeloma